Skip to Content

David Fogelman

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1998 Albert Einstein College of Medicine, Bronx, NY, MD, Medical Doctorate
1994 Cornell University, Ithaca, NY, BS, Biology

Board Certifications

10/2006 Hematology
11/2005 Medical Oncology
2001 Internal Medicine


Institutional Committee Activities

Associate Member, MDACC Institutional Review Board #5, 2008-2009
Member, MDACC CME Advisory Committee, 2008-2009

Selected Publications

Peer-Reviewed Original Research Articles

1. Fogelman DR, Kopetz S, Eng C. Emerging Drugs for Colorectal Cancer. Expert Opin Emerg Drugs 13(4):629-42, 12/2008. PMID: 19046131.
2. Blazer DG III, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover KY, Wolff RA, Curley SA, Abdalla EK, Vauthey JN. Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases. J Clin Oncol 26(33):5344-51, 11/2008. e-Pub 10/2008. PMID: 18936472.
3. Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, Abbruzzese JL, Ajani JA, Wolff RA. Chemotherapy with 5-Fluorouracil and a Platinum Compound Improves Outcomes in Metastatic Small Bowel Adenocarcinoma. Cancer 113(8):2038-45, 10/2008. PMID: 18759326.
4. Overman MJ, Fogelman D, Al-Kali A, Crane CH, Evans D, Abdalla EK, Pisters P, Kopetz S, Eng C, Wolff RA. Aggressive Combined Modality Therapy for Recurrent Colorectal Cancer Involving the Duodenum and Pancreas: A Report of Five Cases. Clin Colorectal Cancer 7(5):338-42, 9/2008. PMID: 18794067.
5. Fine RL, Fogelman DR, Schreibman SM, Desai M, Sherman W, Strauss J, Guba S, Andrade R, Chabot J. The Gemcitabine, Docetaxel, and Capecitabine (GTX) Regimen for Metastatic Pancreatic Cancer: A Retrospective Analysis. Cancer Chemother Pharmacol 61/1(1):167-175, 1/2008. e-Pub 4/18/2007. PMID: 17440727.
6. Fine RL, Shah SS, Moulton TA, Yu IR, Fogelman DR. Androgen and c-Kit Receptors in Desmoplastic Small Round Cell Tumors Resistant to Chemotherapy: Novel Targets for Therapy. Cancer Chemother Pharmacol 59/4(4):429-437, 3/2007. e-Pub 8/3/2006. PMID: 16896931.
7. Fogelman DR, Chen J, Chabot JA, Allendorf JD, Schrope BA, Ennis RD, Schreibman SM, Fine RL. The Evolution of Adjuvant and Neoadjuvant Chemotherapy and Radiation for Advanced Pancreatic Cancer: from 5-fluorouracil to GTX. Surg Oncol Clin N Am 13(4):711-35 x. Review, 10/2004. PMID: 15350944.

Invited Articles

1. Fogelman DR, Overman MJ, Varadhachary G, Fortuno ME. Neoadjuvant Chemoradiation for Resectable and Borderline Pancreatic Cancer. Applied Cancer Research 28(4):127-133, 12/2008.
2. Fogelman DR, Fine RL. Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine/Docetaxel/Capecitabine. Case Studies in Oncology 5/1, 2003.


1. Fogelman DR, Abbruzzese JL. Inoperable Pancreatic Cancer: Standard of Care. Oncology 21/13, 2007.


1. Hassabo HM, Hassan MM, George B, Wen S, Baladandayuthapani V, Kopetz S, Fogelman D, Kee BK, Eng C, Garrett CR. Retrospective Evaluation of Patients with Colorectal Cancer (CRC) and type II Non Insulin Dependent Diabetes (NIDDM). 2011 Gastrointestinal Cancers Symposium, 1/2011.

Manuals, Teaching Aids, Other Teaching Publications

1. Fogelman, D. Final Result of a Phase II Trial of Gemcitabine, Oxaliplatin, and Bevacizumab in locally advanced and metastatic pancreatic cancer. Submitted.

Last updated: 6/27/2014